Evidence map›Paper›PMID 42741955›Full record

ArticleAnnals of medicine2026

Risk factors for future exacerbations in patients with COPD treated with dual LABA/LAMA.

Qing Song, Tingting Chen, Dan Peng, Chengrui Liu, Rensen Xiao, Qinqin Yao, Xiaoling Guo, Longhua Sun, Wenxin Yuan, Fang Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qing SongPostdoctoral Innovation Practice Base, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.
Tingting ChenDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Dan PengDepartment of General Medicine, The Fourth People's Hospital of Nanchang County, Nanchang, Jiangxi, China.
Chengrui LiuDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Rensen XiaoDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Qinqin YaoDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Xiaoling GuoDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Longhua SunDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Wenxin YuanUltrasound Department, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Fang HuangDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 report revised the combined chronic obstructive pulmonary disease (COPD) assessment. Patients in groups B and E are recommended dual long-acting β

methodsThis was a retrospective cohort study. Baseline data included demographic characteristics, pulmonary function, symptom scores, GOLD grades, GOLD groups, the number of exacerbations and hospitalizations in the past year, LABA/LAMA, and comorbidities were collected. The number of future exacerbations was collected during one year of follow-up.

resultsA total of 1076 patients with COPD were included. There were 284 (26.4%) patients experienced exacerbations during follow-up. Patients who experienced exacerbations were older and had higher clinical COPD questionnaire scores, a great number of exacerbations and hospitalizations in the past year, and a higher proportion of GOLD grades 3-4. Logistic regression analysis showed that GOLD grades 3-4 (odds ratio [OR] = 1.343, 95% confidence intervals [CI] = 1.016-1.776), one exacerbation in the past year (OR = 1.763, 95% CI = 1.248-2.489), and ≥ 2 exacerbations in the past year (OR = 2.514, 95% CI = 1.792-3.525) were independent risk factors for experiencing exacerbations. Furthermore, in group B, logistic regression analysis showed that GOLD grades 3-4 (OR = 1.808, 95% CI = 1.096-2.981) and hypertension (OR = 3.400, 95% CI = 1.712-6.752) were independent risk factors for experiencing exacerbations. In group E, logistic regression analysis showed that ≥ 2 exacerbations in the past year (OR = 1.426, 95% CI = 1.021-1.993) was an independent risk factor for experiencing exacerbations.

conclusionsPatients with COPD treated with LABA/LAMA remained at high risk of future exacerbations. GOLD grades 3-4 and exacerbations in the past year were associated with future exacerbations and may warrant particular attention from clinicians.

Indexed as

Adrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveAdministration, InhalationAgedDisease ProgressionDrug Therapy, CombinationFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSeverity of Illness IndexAdrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsChronic obstructive pulmonary diseaseexacerbationGOLD gradesLaba/LAMA

Identifiers

PMID42741955
PMCPMC13580378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.